How to Outsource Blood Products and Plasma Regulation Without Losing Control

Blood products and plasma regulation is a critical area of biologics regulation with stringent oversight from various regulatory agencies across the globe. The increasing demand for plasma-derived therapies and blood-based products necessitates a strong understanding of regulatory requirements and guidelines to ensure compliance and successful market access. This article serves as a detailed regulatory explainer manual designed for professionals in Regulatory Affairs (RA), Chemistry, Manufacturing, and Controls (CMC), and labelling teams operating in the US, UK, and EU.

Context

Blood products encompass a variety of therapeutic agents derived from human blood, including but not limited to plasma, red blood cells, platelets, and clotting factors. The regulatory framework surrounding these products is multifaceted and involves compliance with both national and international guidelines. Blood products are classified as biologics and are subject to specific regulations that differ from traditional pharmaceutical products.

Legal/Regulatory Basis

The legal framework for blood products and plasma regulation varies by region:

• United States: The regulatory basis for blood products is primarily governed by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA). Specific regulations can be found in 21 CFR Part 600 – 680.
• European Union: In the EU, blood products are regulated under the European Medicines Agency (EMA), specifically Directive 2002/98/EC and its corresponding guidelines, which outline the standards for the collection, testing, processing, storage, and distribution of blood and blood components.
• United Kingdom: Following Brexit, the UK maintains its own guidelines for blood products under the UK Medicines and Healthcare products Regulatory Agency (MHRA), aligning closely with the former EU framework but with some deviations.

Documentation

Proper documentation is essential for compliance with regulatory requirements. Key documents typically include:

• Applications and Submissions: Regulatory submissions such as Investigational New Drug Applications (INDs), Biologics License Applications (BLAs), and Marketing Authorisation Applications (MAAs).
• Quality Management Systems: Comprehensive documentation concerning the quality management systems (QMS) in place, including standard operating procedures (SOPs) for production and safety testing.
• Clinical Trial Data: Data generated from clinical trials, including protocols, informed consent forms, and case report forms.
• Post-Market Surveillance: Documentation of ongoing safety and efficacy monitoring once products are on the market.

Review/Approval Flow

The typical review and approval flow for blood products involves several stages, starting from preclinical development to post-market surveillance:

1. Preclinical Development: Conduct non-clinical studies to establish safety and efficacy.
2. Clinical Trials: Submit IND to FDA or comparable applications in EU/UK before starting clinical trials.
3. Marketing Approval: Submit BLA or MAA after successful clinical trial completion.
4. Regulatory Review: Engage with regulatory agencies through formal meetings during the review process for guidance and clarification.
5. Post-Approval Compliance: Monitor product performance and compliance with regulatory commitments, including safety reporting.

Common Deficiencies

When outsourcing blood product and plasma regulation, companies can encounter several common deficiencies that may hinder approval timelines:

• Inconsistent Quality Standards: Lack of adherence to established quality standards can lead to significant compliance issues.
• Incomplete Documentation: Failing to submit complete documentation can result in delayed approvals.
• Poor Communication with Regulatory Authorities: Insufficient interaction can lead to misunderstandings and longer review periods.
• Inadequate Risk Management Strategies: Not addressing risk factors associated with the outsourcing process can result in adverse regulatory consequences.

Regulatory Affairs Decision Points

Determining When to File as Variation vs. New Application

When considering regulatory submissions, it is crucial to evaluate whether changes in product formulation, manufacturing processes, or indications warrant a new application or can be submitted as a variation. The following decision points can guide the process:

• If the change significantly alters the product’s identity, safety, or efficacy, a new application is typically required.
• For minor changes that do not affect the overall product profile, submissions can be made as variations, provided they meet defined regulatory thresholds.

Justifying Bridging Data

In the context of outsourcing, justifying the use of bridging data during regulatory submissions can be pivotal. Bridging data allows companies to demonstrate comparability between products manufactured at different sites or using different processes.

When preparing to justify bridging data, consider the following:

• Scientific Rationale: Provide a valid scientific rationale supporting the choice of bridging data over traditional study results.
• Comprehensive Analyses: Include extensive analytical data that encompasses quality attributes and clinical relevance.
• Historical Comparison: Reference historical data to emphasize consistency in safety and efficacy profiles clouting the bridging data.

Interaction with Other Departments

The function of Regulatory Affairs in the context of blood products is intrinsically linked with other departments:

• CMC: Close collaboration with CMC is essential to ensure that the manufacturing process remains compliant with regulatory expectations. RA must ensure that any changes in the manufacturing process are correctly documented and submitted.
• Clinical: Regulatory must ensure that clinical trials are designed with compliance in mind, addressing regulatory agency expectations regarding endpoints, safety assessments, and ethical considerations.
• Pharmacovigilance (PV): Regulatory Affairs coordinates with PV to ensure adherence to post-market reporting requirements, including adverse event reporting and risk management plans.
• Quality Assurance (QA): RA collaborates closely with QA to maintain compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP).
• Commercial: Engaging with the Commercial team allows Regulatory to assist in navigating the market access landscape, ensuring that product claims align with regulatory approvals.

Practical Tips for Documentation, Justifications, and Responses

To navigate the complexities of blood products and plasma regulation effectively, regulatory professionals should consider the following practical tips:

• Establish a Clear Governance Framework: Define roles and responsibilities for regulatory compliance within your organization to streamline processes.
• Implement Early Regulatory Assessment: Conduct pre-submission meetings with regulatory agencies wherever possible to receive early feedback on submission strategies.
• Prioritize Quality and Compliance: Ensure that all documentation related to quality is meticulously prepared and reviewed to prevent deficiencies during agency review.
• Be Proactive in Communication: Maintain open lines of communication with regulatory authorities to mitigate potential issues and clarify uncertainties.
• Leverage Regulatory Intelligence: Stay informed of updates to regulations, guidance documents, and agency expectations to adjust compliance strategies accordingly.

Conclusion

Outsourcing blood products and plasma regulation presents unique challenges that demand rigorous attention to regulatory compliance, documentation, and communication strategies. Regulatory Affairs professionals must remain vigilant and proactive to align with agency expectations while mitigating the risks associated with outsourcing. By following established guidelines, maintaining comprehensive documentation, and engaging in cross-departmental collaboration, organizations can ensure successful market access and adherence to the evolving landscape of biologics regulation.